Medtronic has finalised a US$90m investment in Anteris Technologies, a Minnesota medtech firm developing TAVR valve technology.
Anteris focuses on structural heart technologies and is known for its biomimetic DurAVR transcatheter heart valve (THV) system, which the company says is the first of its kind.
The DurAVR valve is made from a single piece of anti-calcification ADAPT tissue patented by Anteris and is designed to mimic the performance of a healthy aortic valve.
Anteris first announced the proposed strategic investment from Medtronic on 20 January.
The deal closed immediately after Anteris completed a public offering of common stock.
In total, the company raised combined gross proceeds of US$320m, which it said will go towards continuing research on the DurAVR THV system.
Wayne Paterson is vice chairman and chief executive of Anteris.
He said in a statement: “This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company.
“It also provides strong validation of our programme from the capital markets and a major strategic innovator.
“The investment is one aspect of a collaboration that may expand into other strategic areas in the future.”
The DurAVR THV system has not yet been approved by the US Food and Drug Administration (FDA).
However, the FDA approved PARADIGM, a global pivotal trial focused on the device’s safety and effectiveness, in November 2025.
The trial is expected to enrol about 1,000 patients from the US, Europe and Canada.
Anteris also released data on 100 patients who received the DurAVR THV system in 2025.
It said the valve was linked to positive 30-day clinical outcomes and no valve-related mortality, with a technical success rate of 100 per cent for the final 50 patients.
In 2024, researchers presented one-year data on the first patients to receive the DurAVR THV system.
The valve was successfully implanted in all 28 patients, with no signs of severe or moderate aortic stenosis after 12 months.
Jorie Soskin is vice president and general manager of Medtronic’s structural heart business.
Soskin said: Our investment in differentiated innovation like the DurAVR THV technology, which has the potential to offer improved valve performance in a balloon-expandable platform, is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio.”
